Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration.

Patel MM, Nielsen DA, Kosten TR, De La Garza R 2nd, Newton TF, Verrico CD.

Am J Addict. 2018 Oct;27(7):567-573. doi: 10.1111/ajad.12788. Epub 2018 Aug 20.

PMID:
30126012
2.

Comparison of three measurement models of discounting among individuals with methamphetamine use disorder.

Yoon JH, Weaver MT, De La Garza R 2nd, Suchting R, Nerumalla CS, Omar Y, Brown GS, Haliwa I, Newton TF.

Am J Addict. 2018 Jul 19. doi: 10.1111/ajad.12761. [Epub ahead of print]

PMID:
30024076
3.

Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.

Yammine L, Kosten TR, Cinciripini PM, Green CE, Meininger JC, Minnix JA, Newton TF.

Medicine (Baltimore). 2018 Jan;97(2):e9567. doi: 10.1097/MD.0000000000009567.

4.

A COMPARISON OF MAZUR'S k AND AREA UNDER THE CURVE FOR DESCRIBING STEEP DISCOUNTERS.

Yoon JH, De La Garza R 2nd, Newton TF, Suchting R, Weaver MT, Brown GS, Omar Y, Haliwa I.

Psychol Rec. 2017 Sep;67(3):355-363. doi: 10.1007/s40732-017-0220-9. Epub 2017 Mar 9.

5.

The limited impact that cocaine use patterns have on neurocognitive functioning in individuals with cocaine use disorder.

Mahoney JJ 3rd, Kalechstein AD, Newton TF, De La Garza R 2nd.

J Psychopharmacol. 2017 Aug;31(8):989-995. doi: 10.1177/0269881117715606. Epub 2017 Jul 11.

PMID:
28695777
6.

Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study.

Mathai DS, Holst M, Rodgman C, Haile CN, Keller J, Hussain MZ, Kosten TR, Newton TF, Verrico CD.

J Neuropsychiatry Clin Neurosci. 2018 Winter;30(1):66-76. doi: 10.1176/appi.neuropsych.16120328. Epub 2017 Jun 23.

PMID:
28641496
7.

Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genes.

Patriquin MA, Hamon SC, Harding MJ, Nielsen EM, Newton TF, De La Garza R 2nd, Nielsen DA.

Psychiatr Genet. 2017 Oct;27(5):178-186. doi: 10.1097/YPG.0000000000000178.

8.

Electrocardiographic characteristics in individuals with cocaine use disorder.

Mahoney JJ 3rd, Haile CN, De La Garza R 2nd, Thakkar H, Newton TF.

Am J Addict. 2017 Apr;26(3):221-227. doi: 10.1111/ajad.12524. Epub 2017 Mar 1.

PMID:
28248441
9.

The relationship between premorbid IQ and neurocognitive functioning in individuals with cocaine use disorders.

Mahoney JJ, Kalechstein AD, De Marco AP, Newton TF, De La Garza R.

Neuropsychology. 2017 Mar;31(3):311-318. doi: 10.1037/neu0000344. Epub 2017 Jan 5.

PMID:
28054825
10.

Treadmill exercise improves fitness and reduces craving and use of cocaine in individuals with concurrent cocaine and tobacco-use disorder.

De La Garza R 2nd, Yoon JH, Thompson-Lake DG, Haile CN, Eisenhofer JD, Newton TF, Mahoney JJ 3rd.

Psychiatry Res. 2016 Nov 30;245:133-140. doi: 10.1016/j.psychres.2016.08.003. Epub 2016 Aug 9.

11.

Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Grasing K, Mathur D, DeSouza C, Newton TF, Moody DE, Sturgill M.

Am J Addict. 2016 Aug;25(5):392-9. doi: 10.1111/ajad.12402. Epub 2016 Jul 8.

12.

The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.

Shorter D, Nielsen DA, Hamon SC, Nielsen EM, Kosten TR, Newton TF, De La Garza R 2nd.

Pharmacogenet Genomics. 2016 Sep;26(9):428-35. doi: 10.1097/FPC.0000000000000234.

13.

Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial.

Rodgman C, Verrico CD, Holst M, Thompson-Lake D, Haile CN, De La Garza R 2nd, Raskind MA, Newton TF.

J Clin Psychiatry. 2016 May;77(5):e561-5. doi: 10.4088/JCP.14m09681.

PMID:
27249080
14.

Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.

Verrico CD, Haile CN, De La Garza R 2nd, Grasing K, Kosten TR, Newton TF.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw029. doi: 10.1093/ijnp/pyw029. Print 2016 Jul.

15.

Next Generation Programmable Bio-Nano-Chip System for On-Site Detection in Oral Fluids.

Christodoulides N, De La Garza R 2nd, Simmons GW, McRae MP, Wong J, Newton TF, Kosten TR, Haque A, McDevitt JT.

J Drug Abuse. 2015 Nov 23;1(1):1-6.

16.

Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder.

De La Garza R 2nd, Verrico CD, Newton TF, Mahoney JJ 3rd, Thompson-Lake DG.

Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv098. doi: 10.1093/ijnp/pyv098.

17.

Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans.

Newton TF, Haile CN, Mahoney JJ 3rd, Shah R, Verrico CD, De La Garza R 2nd, Kosten TR.

Psychiatry Res. 2015 Nov 30;230(1):44-9. doi: 10.1016/j.psychres.2015.07.073. Epub 2015 Jul 29.

18.

Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids.

Christodoulides N, De La Garza R 2nd, Simmons GW, McRae MP, Wong J, Newton TF, Smith R, Mahoney JJ III, Hohenstein J, Gomez S, Floriano PN, Talavera H, Sloan DJ, Moody DE, Andrenyak DM, Kosten TR, Haque A, McDevitt JT.

Drug Alcohol Depend. 2015 Aug 1;153:306-13. doi: 10.1016/j.drugalcdep.2015.04.026. Epub 2015 May 22.

19.

Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders.

Brewer AJ 3rd, Nielsen DA, Spellicy CJ, Hamon SC, Gingrich J, Thompson-Lake DG, Nielsen EM, Mahoney JJ 3rd, Kosten TR, Newton TF, De La Garza R 2nd.

Pharmacogenet Genomics. 2015 Jun;25(6):296-304. doi: 10.1097/FPC.0000000000000137.

20.

Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.

De La Garza R 2nd, Bubar MJ, Carbone CL, Moeller FG, Newton TF, Anastasio NC, Harper TA, Ware DL, Fuller MA, Holstein GJ, Jayroe JB, Bandak SI, Reiman KZ, Neale AC, Pickford LB, Cunningham KA.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jun 3;59:40-48. doi: 10.1016/j.pnpbp.2015.01.009. Epub 2015 Jan 17.

Supplemental Content

Loading ...
Support Center